Table 1 Overall baseline clinical characteristics and treatment received
Variable | N = 248 | |
|---|---|---|
Patient related | Parameter | |
Age (years) | 66.92 (12.19) | |
BMI (kg/m2) | 33.56 (7.85) | |
DM duration (years) | 22.44 (9.96) | |
HbA1c % | 8.32 (1.62) | |
Gender:Male | 161 (64.91%) | |
Smoker:Yes | 127 (51.20%) | |
DM:T2 | 210 (84.67%) | |
Drug:Insulin | 182 (73.38%) | |
HTN:Yes | 213 (85.88%) | |
Nephropathy:Yes | 137 (55.24%) | |
Hyperlipidemia:Yes | 225 (90.72%) | |
Eye related | ||
Baseline BCVA (ETDRS letters) | 63.63 (14.93) | |
Baseline CMT (microns) | 381.64 (107.31) | |
DR duration (years) | 8.06 (4.23) | |
Laterality: RE | 123 (49.59%) | |
Lens status: Phakic | 164 (66.12%) | |
PRP:Yes | 106 (42.74%) | |
Focal:Yes | 98 (39.51%) | |
DR severity | ||
Mild NPDR | 53 (21.37%) | |
Moderate NPDR | 74 (29.83%) | |
Severe NPDR | 40 (16.12%) | |
PDR | 81 (32.66%) | |
Drug received | ||
Bevacizumab | 138 (55.64%) | |
Aflibercept | 31 (12.50%) | |
Ranibizumab | 45 (18.14%) | |
Mixed | 34 (13.70%) | |